- Home
- NKTR
NKTR
Nektar Therapeutics
as of 12-12-2025 3:43pm EST
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.1B | IPO Year: | 1994 |
| Target Price: | $106.33 | AVG Volume (30 days): | 603.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.48 - $66.92 | Next Earning Date: | 11-06-2025 |
| Revenue: | $62,600,000 | Revenue Growth: | -32.79% |
| Revenue Growth (this year): | -54.92% | Revenue Growth (next year): | -3.79% |
AI-Powered NKTR Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
Chief Legal Officer
Avg Cost/Share
$54.28
Shares
630
Total Value
$34,196.40
Owned After
21,585
SEC Form 4
President & CEO
Avg Cost/Share
$54.28
Shares
2,207
Total Value
$119,795.96
Owned After
54,245
SEC Form 4
Chief R&D Officer
Avg Cost/Share
$54.28
Shares
1,157
Total Value
$62,801.96
Owned After
18,971
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Nov 25, 2025 | Sell | $54.28 | 630 | $34,196.40 | 21,585 | |
| ROBIN HOWARD W | NKTR | President & CEO | Nov 25, 2025 | Sell | $54.28 | 2,207 | $119,795.96 | 54,245 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Nov 25, 2025 | Sell | $54.28 | 1,157 | $62,801.96 | 18,971 |
Compare NKTR vs Leading Stocks
See how NKTR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.